• Home
  • Autotelic Bio
6
Oct
2026
Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026
stand 2C54
Book a meeting

Autotelic Bio

About Autotelic Bio

Autotelic Bio is a biotechnology company at the forefront of innovative therapeutic development, with a focus on two core areas: novel RNA therapeutics and fixed-dose combination (FDC) drug development. We are advancing antisense oligonucleotide (ASO) therapies for pancreatic cancer, inflammatory skin diseases, and neurodegenerative disorders, as well as fixed-dose combination treatments for chronic diseases.
Our goal is to bring breakthrough therapies to patients through strategic partnerships and out-licensing opportunities, and we are actively seeking collaborations to expand our cutting-edge solutions on a global scale. 

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less

Meet us at

  • CPHI Milan 2026

    CPHI Milan 2026

    Fiera Milano, Italy
    6 Oct 2026 - 8 Oct 2026
    stand 2C54
  • Country/Region:
    Korea, Republic Of
  • On CPHI since:
    2021
  • Employees:
    25 - 49
Company types
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Pharmaceutical Company (innovator finished products)
Contact info
  • +827042863041
  • Website
  • #302, 194-41, Osong-saengmyeong 1-ro, Osong-eup, Chungcheongbuk-do, 28610, Heungdeok-gu, Cheongju-si, Korea, Republic Of
Show contact info Hide contact info

Products from Autotelic Bio (3)

  • ATB-101

    Product ATB-101

    ATB-101 is the world’s first fixed-dose combination of olmesartan and dapagliflozin, designed for patients with hypertension and type 2 diabetes. A Phase 3 study has been completed in Korea, with regulatory approval expected in Q1 2027. U.S. development is progressing through the FDA 505(b)(2) pathway, wit...
  • ATB-720

    Product ATB-720

    ATB-720 is a first-in-class topical antisense oligonucleotide (ASO) candidate for atopic dermatitis. Designed to deliver targeted activity directly to the skin while minimizing systemic exposure, ATB-720 has demonstrated compelling preclinical efficacy and offers a novel, non-steroidal treatment approach.
  • ATB-810

    Product ATB-810

    ATB-810 is a first-in-class antisense oligonucleotide (ASO) candidate for the treatment of ALS and progressive multiple sclerosis. Powered by Autotelic Bio’s proprietary C-Duplex™ technology, it is designed to achieve broad brain distribution and improved tolerability, with compelling efficacy demonstrated...